Results 211 to 220 of about 125,582 (281)

Association Between Postoperative NSAID Use and Bleeding Following Transoral Robotic Surgery

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate the safety and outcomes of NSAID use following transoral robotic surgery (TORS). Study Design Retrospective cohort study using propensity score matching. Setting Multi‐institutional database (TriNetX). Methods Patients undergoing TORS were identified using ICD‐10 codes.
Brayden Seliger, Jacob Beiriger, Milana Berry, Nilam Patel, Richard B. Cannon, Marcus M. Monroe, Hilary C. McCrary   +6 more
wiley   +1 more source

A ready-to-use deep eutectic solvent-immersed polypropylene fabric cap microextraction strategy for nonsteroidal anti-inflammatory drugs analysis in plasma: a proof-of-concept study. [PDF]

RSC Adv
Dong JY, Wang RJ, Yang XB, Liu YF, Ran Q, Chen D.   +5 more
europepmc   +1 more source

Rehabilitation and return to activity after platelet‐rich plasma injections in chronic tendinopathies: Consensus from international experts

PM&R, EarlyView.
Abstract Background The effectiveness of platelet‐rich plasma (PRP) injections in chronic tendinopathies remains debated. Although the product's characteristics play a role, the impact of postinjection recommendations remains poorly investigated. Objective To establish principles and guidelines for post‐PRP injection rehabilitation and return to ...
Vincent Gremeaux, Martin Lamontagne, Valérie Bélanger, Etienne Dalmais, Eric Noël, Alain Frey, Paul Ornetti, Fadoua Allali, Jimmy Gross, F. Michel, Hervé Bard, Jean‐François Kaux, the GRIIP (Groupe de Recherche International sur les Injections de Plaquettes; International Research Group on Platelet Injections)   +12 more
wiley   +1 more source

Navigating Chronic Pain in Patients with Cirrhosis: Unique Analgesic Considerations and Non-Pharmacologic Options. [PDF]

Curr Hepatol Rep
Deng LX, Rubin JB.
europepmc   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

An Update on Pain Management in Pediatric Spine Surgery. [PDF]

Curr Rev Musculoskelet Med
Kiani SN, Bach K, Kwok V, Swarup I.
europepmc   +1 more source

When neck pain isn't muscular: A case report on TIPIC syndrome responding to NSAIDs. [PDF]

Radiol Case Rep
Bellamlih H, El Farouki A, Belabbes S, Zinoun B, Africha T.   +4 more
europepmc   +1 more source

Impact of fibromyalgia on patient acceptable symptom state in Thai patients with spondyloarthritis: A cross‐sectional study

Rheumatology &Autoimmunity, EarlyView.
This cross‐sectional study enrolled Thai patients with spondyloarthritis to assess the prevalence and its impact. Fibromyalgia was present in 5.5% and significantly impaired health‐related quality of life and symptom perception. Low disease activity, good sleep quality, and FS < 3 were independently associated with achieving PASS.
Sittikorn Srivorrapattararkul, Praveena Chiowchanwisawakit   +1 more
wiley   +1 more source

Impact of NSAID type, initiation timing, duration and dose on clinical outcomes of immunotherapy in NSCLC: a multicenter two-cohort study. [PDF]

J Immunother Cancer
Li Y, Jia X, Liu M, Zhu Z, Qiao H, Jiang J, Li M, Xia W, Xu L, Zhang E, Wang W, Liu J, Xu R, Qi Y, Jing G, Bai Y, Jiao M, Hu S, Liu Z, Guo H, Jiang L.   +20 more
europepmc   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source